Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Causal Inference Engine: a platform for directional gene set enrichment analysis and inference of active transcriptional regulators.

Farahmand S, O'Connor C, Macoska JA, Zarringhalam K.

Nucleic Acids Res. 2019 Dec 16;47(22):11563-11573. doi: 10.1093/nar/gkz1046.

PMID:
31701125
2.

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing.

Liu TT, Rodgers AC, Nicholson TM, Macoska JA, Marker PC, Vezina CM, Bjorling DE, Roldan-Alzate A, Hernando D, Lloyd GL, Hacker TA, Ricke WA.

J Vis Exp. 2019 Aug 14;(150). doi: 10.3791/59802.

PMID:
31475976
3.

Forkhead domain mutations in FOXA1 drive prostate cancer progression.

Gao S, Chen S, Han D, Barrett D, Han W, Ahmed M, Patalano S, Macoska JA, He HH, Cai C.

Cell Res. 2019 Sep;29(9):770-772. doi: 10.1038/s41422-019-0203-2. Epub 2019 Jul 19. No abstract available.

PMID:
31324883
4.

Prostate Transition Zone Fibrosis is Associated with Clinical Progression in the MTOPS Study.

Macoska JA, Uchtmann KS, Leverson GE, McVary KT, Ricke WA.

J Urol. 2019 Dec;202(6):1240-1247. doi: 10.1097/JU.0000000000000385. Epub 2019 Jun 12.

PMID:
31188728
5.

Inhibition of the CXCL12/CXCR4 axis prevents periurethral collagen accumulation and lower urinary tract dysfunction in vivo.

Macoska JA, Wang Z, Virta J, Zacharias N, Bjorling DE.

Prostate. 2019 May;79(7):757-767. doi: 10.1002/pros.23781. Epub 2019 Feb 27.

PMID:
30811623
6.

TMPRSS2-ERG activates NO-cGMP signaling in prostate cancer cells.

Zhou F, Gao S, Han D, Han W, Chen S, Patalano S, Macoska JA, He HH, Cai C.

Oncogene. 2019 May;38(22):4397-4411. doi: 10.1038/s41388-019-0730-9. Epub 2019 Feb 4.

7.

Nonalcoholic Fatty Liver Disease Demonstrates a Pre-fibrotic and Premalignant Molecular Signature.

Almanza D, Gharaee-Kermani M, Zhilin-Roth A, Rodriguez-Nieves JA, Colaneri C, Riley T, Macoska JA.

Dig Dis Sci. 2019 May;64(5):1257-1269. doi: 10.1007/s10620-018-5398-4. Epub 2018 Dec 5.

8.

Augmentation Cystoplasty of Diseased Porcine Bladders with Bi-Layer Silk Fibroin Grafts.

Affas S, Schäfer FM, Algarrahi K, Cristofaro V, Sullivan MP, Yang X, Costa K, Sack B, Gharaee-Kermani M, Macoska JA, Gundogdu G, Seager C, Estrada CR Jr, Mauney JR.

Tissue Eng Part A. 2019 Jun;25(11-12):855-866. doi: 10.1089/ten.TEA.2018.0113. Epub 2018 Oct 26.

PMID:
30191762
9.

Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer.

Han W, Gao S, Barrett D, Ahmed M, Han D, Macoska JA, He HH, Cai C.

Oncogene. 2018 Feb 8;37(6):710-721. doi: 10.1038/onc.2017.385. Epub 2017 Oct 23.

10.

Preface to the human microbiome in urologic health and disease.

Shoskes DA, Macoska JA.

Ann Transl Med. 2017 Jan;5(2):27. doi: 10.21037/atm.2017.01.12. No abstract available.

11.

Androgen receptor variants: another twist in the plot.

Macoska JA.

Oncotarget. 2017 Mar 7;8(10):16100. doi: 10.18632/oncotarget.15130. No abstract available.

12.

A novel nonsense mutation in androgen receptor confers resistance to CYP17 inhibitor treatment in prostate cancer.

Han D, Gao S, Valencia K, Owiredu J, Han W, de Waal E, Macoska JA, Cai C.

Oncotarget. 2017 Jan 24;8(4):6796-6808. doi: 10.18632/oncotarget.14296.

13.

Androgen Receptor Tumor Suppressor Function Is Mediated by Recruitment of Retinoblastoma Protein.

Gao S, Gao Y, He HH, Han D, Han W, Avery A, Macoska JA, Liu X, Chen S, Ma F, Chen S, Balk SP, Cai C.

Cell Rep. 2016 Oct 18;17(4):966-976. doi: 10.1016/j.celrep.2016.09.064.

14.

In-Depth Characterization and Validation of Human Urine Metabolomes Reveal Novel Metabolic Signatures of Lower Urinary Tract Symptoms.

Hao L, Greer T, Page D, Shi Y, Vezina CM, Macoska JA, Marker PC, Bjorling DE, Bushman W, Ricke WA, Li L.

Sci Rep. 2016 Aug 9;6:30869. doi: 10.1038/srep30869.

15.

CXCL12/CXCR4 Axis Activation Mediates Prostate Myofibroblast Phenoconversion through Non-Canonical EGFR/MEK/ERK Signaling.

Rodríguez-Nieves JA, Patalano SC, Almanza D, Gharaee-Kermani M, Macoska JA.

PLoS One. 2016 Jul 19;11(7):e0159490. doi: 10.1371/journal.pone.0159490. eCollection 2016.

16.

Resveratrol-Mediated Repression and Reversion of Prostatic Myofibroblast Phenoconversion.

Gharaee-Kermani M, Moore BB, Macoska JA.

PLoS One. 2016 Jul 1;11(7):e0158357. doi: 10.1371/journal.pone.0158357. eCollection 2016.

17.

Signaling mechanisms coupled to CXCL12/CXCR4-mediated cellular proliferation are PTEN-dependent.

Begley LA, Kasina S, Shah RB, Macoska JA.

Am J Clin Exp Urol. 2015 Aug 8;3(2):91-9. eCollection 2015.

18.

Complex cellular composition of solitary fibrous tumor of the prostate.

Gharaee-Kermani M, Mehra R, Robinson DR, Wei JT, Macoska JA.

Am J Pathol. 2014 Mar;184(3):732-9. doi: 10.1016/j.ajpath.2013.11.024. Epub 2014 Jan 13.

19.

Promising molecular targets and biomarkers for male BPH and LUTS.

Gharaee-Kermani M, Macoska JA.

Curr Urol Rep. 2013 Dec;14(6):628-37. doi: 10.1007/s11934-013-0368-z. Review.

20.

Prostatic fibrosis, lower urinary tract symptoms, and BPH.

Rodriguez-Nieves JA, Macoska JA.

Nat Rev Urol. 2013 Sep;10(9):546-50. doi: 10.1038/nrurol.2013.149. Epub 2013 Jul 16. Review.

21.

Obesity-induced diabetes and lower urinary tract fibrosis promote urinary voiding dysfunction in a mouse model.

Gharaee-Kermani M, Rodriguez-Nieves JA, Mehra R, Vezina CA, Sarma AV, Macoska JA.

Prostate. 2013 Jul;73(10):1123-33. doi: 10.1002/pros.22662. Epub 2013 Mar 26.

22.

Nanoroughened surfaces for efficient capture of circulating tumor cells without using capture antibodies.

Chen W, Weng S, Zhang F, Allen S, Li X, Bao L, Lam RH, Macoska JA, Merajver SD, Fu J.

ACS Nano. 2013 Jan 22;7(1):566-75. doi: 10.1021/nn304719q. Epub 2012 Dec 5.

23.

CXC-type chemokines promote myofibroblast phenoconversion and prostatic fibrosis.

Gharaee-Kermani M, Kasina S, Moore BB, Thomas D, Mehra R, Macoska JA.

PLoS One. 2012;7(11):e49278. doi: 10.1371/journal.pone.0049278. Epub 2012 Nov 16.

24.

CCL11 (eotaxin-1): a new diagnostic serum marker for prostate cancer.

Agarwal M, He C, Siddiqui J, Wei JT, Macoska JA.

Prostate. 2013 May;73(6):573-81. doi: 10.1002/pros.22597. Epub 2012 Oct 11.

25.

Prostatic fibrosis is associated with lower urinary tract symptoms.

Ma J, Gharaee-Kermani M, Kunju L, Hollingsworth JM, Adler J, Arruda EM, Macoska JA.

J Urol. 2012 Oct;188(4):1375-81. doi: 10.1016/j.juro.2012.06.007. Epub 2012 Aug 17.

26.

The CXCL12/CXCR4 axis promotes ligand-independent activation of the androgen receptor.

Kasina S, Macoska JA.

Mol Cell Endocrinol. 2012 Apr 4;351(2):249-63. doi: 10.1016/j.mce.2011.12.015. Epub 2012 Jan 8.

27.

Developmental, cellular and molecular biology of benign prostatic hyperplasia.

Ricke WA, Macoska JA, Cunha GR.

Differentiation. 2011 Nov-Dec;82(4-5):165-7. doi: 10.1016/j.diff.2011.08.005. Epub 2011 Aug 30. No abstract available.

28.

The PCa Tumor Microenvironment.

Sottnik JL, Zhang J, Macoska JA, Keller ET.

Cancer Microenviron. 2011 Dec;4(3):283-97. doi: 10.1007/s12307-011-0073-8. Epub 2011 Jul 5.

29.

Chemokines and BPH/LUTS.

Macoska JA.

Differentiation. 2011 Nov-Dec;82(4-5):253-60. doi: 10.1016/j.diff.2011.04.003. Epub 2011 May 19. Review.

30.

Leukocytic promotion of prostate cellular proliferation.

McDowell KL, Begley LA, Mor-Vaknin N, Markovitz DM, Macoska JA.

Prostate. 2010 Mar 1;70(4):377-89. doi: 10.1002/pros.21071.

31.

ADAM-mediated amphiregulin shedding and EGFR transactivation.

Kasina S, Scherle PA, Hall CL, Macoska JA.

Cell Prolif. 2009 Dec;42(6):799-812. doi: 10.1111/j.1365-2184.2009.00645.x. Epub 2009 Sep 7.

32.

-(-)Gossypol promotes the apoptosis of bladder cancer cells in vitro.

Macoska JA, Adsule S, Tantivejkul K, Wang S, Pienta KJ, Lee CT.

Pharmacol Res. 2008 Nov-Dec;58(5-6):323-31. doi: 10.1016/j.phrs.2008.09.005. Epub 2008 Sep 16.

PMID:
18840529
33.

The inflammatory microenvironment of the aging prostate facilitates cellular proliferation and hypertrophy.

Begley LA, Kasina S, MacDonald J, Macoska JA.

Cytokine. 2008 Aug;43(2):194-9. doi: 10.1016/j.cyto.2008.05.012. Epub 2008 Jun 24.

34.

Novel surface expression of reticulocalbin 1 on bone endothelial cells and human prostate cancer cells is regulated by TNF-alpha.

Cooper CR, Graves B, Pruitt F, Chaib H, Lynch JE, Cox AK, Sequeria L, van Golen KL, Evans A, Czymmek K, Bullard RS, Donald CD, Sol-Church K, Gendernalik JD, Weksler B, Farach-Carson MC, Macoska JA, Sikes RA, Pienta KJ.

J Cell Biochem. 2008 Aug 15;104(6):2298-309. doi: 10.1002/jcb.21785.

35.

CXCL5 promotes prostate cancer progression.

Begley LA, Kasina S, Mehra R, Adsule S, Admon AJ, Lonigro RJ, Chinnaiyan AM, Macoska JA.

Neoplasia. 2008 Mar;10(3):244-54.

36.

SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines.

Demichelis F, Greulich H, Macoska JA, Beroukhim R, Sellers WR, Garraway L, Rubin MA.

Nucleic Acids Res. 2008 Apr;36(7):2446-56. doi: 10.1093/nar/gkn089. Epub 2008 Feb 27.

37.

Pilot and feasibility study of serum chemokines as markers to distinguish prostatic disease in men with low total serum PSA.

Macoska JA, Begley LA, Dunn RL, Siddiqui J, Wei JT, Sarma AV.

Prostate. 2008 Mar 1;68(4):442-52. doi: 10.1002/pros.20717.

38.

CXCL12 activates a robust transcriptional response in human prostate epithelial cells.

Begley LA, MacDonald JW, Day ML, Macoska JA.

J Biol Chem. 2007 Sep 14;282(37):26767-74. Epub 2007 Jul 12.

39.

Ancestry, genetic susceptibility, E-cadherin-160A and prostate cancer risk-is there an association?

Macoska JA.

J Urol. 2006 Aug;176(2):435-6. No abstract available.

PMID:
16813859
40.

Prostate cancer cells regulate growth and differentiation of bone marrow endothelial cells through TGFbeta and its receptor, TGFbetaRII.

Barrett JM, Rovedo MA, Tajuddin AM, Jilling T, Macoska JA, MacDonald J, Mangold KA, Kaul KL.

Prostate. 2006 May 1;66(6):632-50.

41.

CXCL12 overexpression and secretion by aging fibroblasts enhance human prostate epithelial proliferation in vitro.

Begley L, Monteleon C, Shah RB, Macdonald JW, Macoska JA.

Aging Cell. 2005 Dec;4(6):291-8.

42.

Concordant copy number and transcriptional activity of genes mapping to derivative chromosomes 8 during cellular immortalization in vitro.

Begley L, Keeney D, Beheshti B, Squire JA, Kant R, Chaib H, MacDonald JW, Rhim J, Macoska JA.

Genes Chromosomes Cancer. 2006 Feb;45(2):136-46.

43.

Evolution of 8p loss in transformed human prostate epithelial cells.

Macoska JA, Paris P, Collins C, Andaya A, Beheshti B, Chaib H, Kant R, Begley L, MacDonald JW, Squire JA.

Cancer Genet Cytogenet. 2004 Oct 1;154(1):36-43.

PMID:
15381370
44.

Genomic and expression analysis of the 8p11-12 amplicon in human breast cancer cell lines.

Ray ME, Yang ZQ, Albertson D, Kleer CG, Washburn JG, Macoska JA, Ethier SP.

Cancer Res. 2004 Jan 1;64(1):40-7.

45.

Haploinsufficiency and reduced expression of genes localized to the 8p chromosomal region in human prostate tumors.

Chaib H, MacDonald JW, Vessella RL, Washburn JG, Quinn JE, Odman A, Rubin MA, Macoska JA.

Genes Chromosomes Cancer. 2003 Jul;37(3):306-13.

46.

LuCaP 35: a new model of prostate cancer progression to androgen independence.

Corey E, Quinn JE, Buhler KR, Nelson PS, Macoska JA, True LD, Vessella RL.

Prostate. 2003 Jun 1;55(4):239-46.

PMID:
12712403
47.

A neuroendocrine/small cell prostate carcinoma xenograft-LuCaP 49.

True LD, Buhler K, Quinn J, Williams E, Nelson PS, Clegg N, Macoska JA, Norwood T, Liu A, Ellis W, Lange P, Vessella R.

Am J Pathol. 2002 Aug;161(2):705-15.

48.

MIM, a potential metastasis suppressor gene in bladder cancer.

Lee YG, Macoska JA, Korenchuk S, Pienta KJ.

Neoplasia. 2002 Jul-Aug;4(4):291-4.

49.

The progressing clinical utility of DNA microarrays.

Macoska JA.

CA Cancer J Clin. 2002 Jan-Feb;52(1):50-9. Review. No abstract available.

50.

Loss of expression of human spectrin src homology domain binding protein 1 is associated with 10p loss in human prostatic adenocarcinoma.

Macoska JA, Xu J, Ziemnicka D, Schwab TS, Rubin MA, Kotula L.

Neoplasia. 2001 Mar-Apr;3(2):99-104.

Supplemental Content

Loading ...
Support Center